First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2

This randomized, double‐blind, single‐ and multiple‐ascending dose study assessed the pharmacokinetics (PKs), pharmacodynamics, and safety of deucravacitinib (Sotyktu™), a selective and potent small‐molecule inhibitor of tyrosine kinase 2, in 100 (75 active, 25 placebo) healthy volunteers (NCT025346...

Descripción completa

Detalles Bibliográficos
Autores principales: Catlett, Ian M., Aras, Urvi, Hansen, Lars, Liu, Yali, Bei, Di, Girgis, Ihab G., Murthy, Bindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841305/
https://www.ncbi.nlm.nih.gov/pubmed/36325947
http://dx.doi.org/10.1111/cts.13435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841305/
https://www.ncbi.nlm.nih.gov/pubmed/36325947
http://dx.doi.org/10.1111/cts.13435

Ejemplares similares